[HTML][HTML] Synergistic antitumor effect of sorafenib in combination with ATM inhibitor in hepatocellular carcinoma cells
J Liu, Y Liu, L Meng, B Ji, D Yang - International Journal of Medical …, 2017 - ncbi.nlm.nih.gov
Background: Currently, sorafenib is the only systemic chemotherapy drug for advanced
stage Hepatocellular carcinoma (HCC). However, emerging data from some clinical HCC …
stage Hepatocellular carcinoma (HCC). However, emerging data from some clinical HCC …
Synergistic Antitumor Effect of Sorafenib in Combination with ATM Inhibitor in Hepatocellular Carcinoma Cells.
J Liu, Y Liu, L Meng, B Ji, D Yang - International Journal of Medical …, 2017 - europepmc.org
Background: Currently, sorafenib is the only systemic chemotherapy drug for advanced
stage Hepatocellular carcinoma (HCC). However, emerging data from some clinical HCC …
stage Hepatocellular carcinoma (HCC). However, emerging data from some clinical HCC …
[PDF][PDF] Synergistic Antitumor Effect of Sorafenib in Combination with ATM Inhibitor in Hepatocellular Carcinoma Cells
J Liu, Y Liu, L Meng, B Ji… - International Journal of …, 2017 - pdfs.semanticscholar.org
Background: Currently, sorafenib is the only systemic chemotherapy drug for advanced
stage Hepatocellular carcinoma (HCC). However, emerging data from some clinical HCC …
stage Hepatocellular carcinoma (HCC). However, emerging data from some clinical HCC …
[HTML][HTML] Synergistic Antitumor Effect of Sorafenib in Combination with ATM Inhibitor in Hepatocellular Carcinoma Cells
J Liu, Y Liu, L Meng, B Ji, D Yang - International Journal of Medical …, 2017 - medsci.org
Background: Currently, sorafenib is the only systemic chemotherapy drug for advanced
stage Hepatocellular carcinoma (HCC). However, emerging data from some clinical HCC …
stage Hepatocellular carcinoma (HCC). However, emerging data from some clinical HCC …
Synergistic antitumor effect of sorafenib in combination with ATM inhibitor in hepatocellular carcinoma cells
J Liu, Y Liu, L Meng, B Ji, D Yang - International Journal of …, 2017 - experts.umn.edu
Background: Currently, sorafenib is the only systemic chemotherapy drug for advanced
stage Hepatocellular carcinoma (HCC). However, emerging data from some clinical HCC …
stage Hepatocellular carcinoma (HCC). However, emerging data from some clinical HCC …
Synergistic Antitumor Effect of Sorafenib in Combination with ATM Inhibitor in Hepatocellular Carcinoma Cells
J Liu, Y Liu, L Meng, B Ji… - International journal of …, 2017 - pubmed.ncbi.nlm.nih.gov
Background: Currently, sorafenib is the only systemic chemotherapy drug for advanced
stage Hepatocellular carcinoma (HCC). However, emerging data from some clinical HCC …
stage Hepatocellular carcinoma (HCC). However, emerging data from some clinical HCC …
Synergistic Antitumor Effect of Sorafenib in Combination with ATM Inhibitor in Hepatocellular Carcinoma Cells.
J Liu, Y Liu, L Meng, B Ji, D Yang - International Journal of Medical …, 2017 - europepmc.org
Background: Currently, sorafenib is the only systemic chemotherapy drug for advanced
stage Hepatocellular carcinoma (HCC). However, emerging data from some clinical HCC …
stage Hepatocellular carcinoma (HCC). However, emerging data from some clinical HCC …
Synergistic Antitumor Effect of Sorafenib in Combination with ATM Inhibitor in Hepatocellular Carcinoma Cells
J Liu, Y Liu, L Meng, B Ji, D Yang - International Journal of Medical …, 2017 - medsci.org
Background: Currently, sorafenib is the only systemic chemotherapy drug for advanced
stage Hepatocellular carcinoma (HCC). However, emerging data from some clinical HCC …
stage Hepatocellular carcinoma (HCC). However, emerging data from some clinical HCC …